5637Homo sapiens (Human)Cancer cell line
Also known as: HTB9 (Based on the ATCC catalog number.)
Quick Overview
Human bladder cancer cell line with known mutations in TERT and PIK3CA.
Detailed Summary
Research Applications
Key Characteristics
Basic Information
| Database ID | CVCL_0126 |
|---|---|
| Species | Homo sapiens (Human) |
| Tissue Source | Urinary bladder[UBERON:UBERON_0001255] |
Donor Information
| Age | 68 |
|---|---|
| Age Category | Adult |
| Sex | Male |
| Race | caucasian |
Disease Information
| Disease | Bladder carcinoma |
|---|---|
| Lineage | Bladder/Urinary Tract |
| Subtype | Bladder Urothelial Carcinoma |
| OncoTree Code | BLCA |
DepMap Information
| Source Type | ATCC |
|---|---|
| Source ID | ACH-000905_source |
Known Sequence Variations
| Type | Gene/Protein | Description | Zygosity | Note | Source |
|---|---|---|---|---|---|
| MutationSimple | TP53 | p.Arg280Thr (c.839G>C) | Heterozygous | - | Unknown, PubMed=12872257 |
| MutationSimple | TERT | c.1-124C>T (c.228C>T) (C228T) | Unspecified | In promoter | from parent cell line Hep-G2 |
| MutationSimple | RB1 | p.Tyr325Ter (c.975T>A) | Homozygous | - | from parent cell line 5637 |
| MutationSimple | MAPK1 | p.Arg79Lys (c.236G>A) | Heterozygous | - | from parent cell line 5637 |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Loading gene expression data...
Publications
Pan-cancer proteomic map of 949 human cell lines.";
Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Cancer Cell 40:835-849.e8(2022).
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Sellers W.R.
Nature 569:503-508(2019).
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
Cancer Res. 79:1263-1273(2019).
Systematic review: characteristics and preclinical uses of bladder cancer cell lines.
Zuiverloon T.C.M., de Jong F.C., Costello J.C., Theodorescu D.
Bladder Cancer 4:169-183(2018).
A landscape of pharmacogenomic interactions in cancer.";
Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
Cell 166:740-754(2016).
Molecular analysis of urothelial cancer cell lines for modeling tumor biology and drug response.
Tsang S.X., Cai Z.-M., Wu S., Dean M., Costello J.C., Theodorescu D.
Oncogene 36:35-46(2017).
Data for identification of GPI-anchored peptides and omega-sites in cancer cell lines.
Masuishi Y., Kimura Y., Arakawa N., Hirano H.
Data Brief 7:1302-1305(2016).
Identification of glycosylphosphatidylinositol-anchored proteins and omega-sites using TiO2-based affinity purification followed by hydrogen fluoride treatment.
Masuishi Y., Kimura Y., Arakawa N., Hirano H.
J. Proteomics 139:77-83(2016).
Drug-resistant urothelial cancer cell lines display diverse sensitivity profiles to potential second-line therapeutics.
Limbart D.M., Rodel F., Wezel F., Haferkamp A., Cinatl J. Jr.
Transl. Oncol. 8:210-216(2015).
The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies.
Chanock S.J., Valencia A., Real F.X.
BMC Genomics 16:403.1-403.16(2015).
Genomic characterization of three urinary bladder cancer cell lines: understanding genomic types of urinary bladder cancer.
Oliveira P., Santos L.
Tumor Biol. 35:4599-4617(2014).
Identification of mutations in distinct regions of p85 alpha in urothelial cancer.
Knowles M.A.
PLoS ONE 8:E84411-E84411(2013).
Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine.
Hurst C.D., Platt F.M., Knowles M.A.
Eur. Urol. 65:367-369(2014).
TSC1 involvement in bladder cancer: diverse effects and therapeutic implications.
Kwiatkowski D.J.
J. Pathol. 230:17-27(2013).
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
Nature 483:603-607(2012).
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Haber D.A.
Cancer Res. 70:2158-2164(2010).
Signatures of mutation and selection in the cancer genome.";
Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Nature 463:893-898(2010).
Profiling and authentication of human cell lines using short tandem repeat (STR) loci: report from the National Cell Bank of Iran.
Azari S., Ahmadi N., Jeddi-Tehrani M., Shokri F.
Biologicals 35:195-202(2007).
PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors.
Carrato A., Tardon A., Serra C., Real F.X.
Cancer Res. 66:7401-7404(2006).
Assessment by M-FISH of karyotypic complexity and cytogenetic evolution in bladder cancer in vitro.
Knowles M.A.
Genes Chromosomes Cancer 43:315-328(2005).
Novel chromosome findings in bladder cancer cell lines detected with multiplex fluorescence in situ hybridization.
Young B.D., Oliver R.T.D.
Cancer Genet. Cytogenet. 135:139-146(2002).
Molecular genetic analysis of chromosome 9 candidate tumor-suppressor loci in bladder cancer cell lines.
Coulter J., Kennedy W.J., Skilleter A., Habuchi T., Knowles M.A.
Genes Chromosomes Cancer 34:86-96(2002).
Short tandem repeat profiling provides an international reference standard for human cell lines.
Harrison M., Virmani A.K., Ward T.H., Ayres K.L., Debenham P.G.
Proc. Natl. Acad. Sci. U.S.A. 98:8012-8017(2001).
Presence and location of TP53 mutation determines pattern of CDKN2A/ARF pathway inactivation in bladder cancer.
Markl I.D.C., Jones P.A.
Cancer Res. 58:5348-5353(1998).
The 9p21 region in bladder cancer cell lines: large homozygous deletion inactivate the CDKN2, CDKN2B and MTAP genes.
Stadler W.M., Olopade O.I.
Urol. Res. 24:239-244(1996).
p53 mutations in bladder carcinoma cell lines.";
Lippa M., Hatzivassiliou G., Tan J.
Oncol. Res. 6:569-579(1994).
Presence of glycogen and growth-related variations in 58 cultured human tumor cell lines of various tissue origins.
Rousset M., Zweibaum A., Fogh J.
Cancer Res. 41:1165-1170(1981).
Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies.
Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.
Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984).
Absence of HeLa cell contamination in 169 cell lines derived from human tumors.
Fogh J., Wright W.C., Loveless J.D.
J. Natl. Cancer Inst. 58:209-214(1977).
Cultivation, characterization, and identification of human tumor cells with emphasis on kidney, testis, and bladder tumors.
Fogh J.
Natl. Cancer Inst. Monogr. 49:5-9(1978).